Left: Human Skeletal Muscle Cells, HSkMC.
Right: FusedHSkMC (fetal) immunolabeled for desmin (green). Nuclei are visualized with PI (red).
Human Skeletal Muscle Cells (HSkMC) are isolated from the skeletal muscle of limbs from adult or fetal donors. Human Skeletal Muscle Cells can undergo differentiation to exhibit actin and myosin myofilaments. HSkMC from Cell Applications, Inc. provide a useful model system to study many aspects of muscular function and disease.
Skeletal Muscle Cells play an instrumental role in the glucose metabolism and diabetes, therefore select HSkMC lots undergo an additional set of characterization at Cell Applications, Inc. to demonstrate AMPK signaling and responsiveness to insulin stimulation. For more information on Pre-screened Skeletal Muscle Cells click here.
Characterization: Positive for sarcomere myosin.
HSkMC from Cell Applications, Inc. have been used to:
- serve as a differentiated control in a study of developmental regulator genes in hESC (Lee, 2006);
- characterize statin-induced gene expression changes and demonstrate cytotoxic effect of statins in skeletal muscle cells (Morikawa, 2005; Yamazaki, 2006; Xu, 2009);
- identify molecular mechanisms of mitochondrial myopathy and sideroblastic anemia resulting from a missense mutation in the PUS1 gene (Patton, 2005); investigate chemokine-like factor expression in the idiopathic inflammatory myopathies (Chowdhury, 2008); and demonstrate that fasting activates AceCS2 gene expression by inducing KLF15 transcription factor (Yamamoto, 2004);
- characterize human FGFR3-positive sarcoma-initiating stem cells (Hirotsu, 2009), and identify trans-Golgi network proteins and Notch and Hedgehog pathways as putative targets for rhabdomyosarcoma therapy (Kawabata, 2011; Kinigou, 2011; Nagao, 2012);
- show that riluzole muscle relaxant effects are mediated by inhibition of INa and stimulation of BKC-channel activity (Wang, 2008); and develop nitric esters that combine the pharmacological functions of NO and muscle relaxation properties for treatment of muscular diseases (Wang, 2013);
- develop biodegradable polymer-based transgene delivery vectors for muscular dystrophy treatment (Wang, 2012) and design optimal coating for orthopedic metallic implants (Perla, 2005, 2006).
Normal human limb skeletal muscle. Each lot is tested negative for HIV, Hepatitis B, Hepatitis C, mycoplasma, bacteria, and fungi.
2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO.
Ampoule of cryopreserved (150-05f), 500 ml of HSkMC Growth Medium (151-500), and a Subculture Reagent Kit (090K).
Shipped in Transfer Medium at 3rd passage in either flasks or multiwell dishes.
Can be cultured at least 15 doublings
Perla, V., and T.J. Webster. 2006. nano-hydroxyapatite–thermally denatured small intestine sub-mucosa composites for entheses applications. International Journal of nanomedicine. 1:351.
Yamazaki, H., M. Suzuki, T. Aoki, S. Morikawa, T. Maejima, F. Sato, K. Sawanobori, M. Kitahara, T. Kodama, and Y. Saito. 2006. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. Journal of atherosclerosis and thrombosis. 13:295-307.
Zalevsky, J., D. Nguyen, G. Moore, S. Ezhevsky, J. Desjarlais, A. Chirino, D. Cash, and M. Bernett. 2006. Rational Chemical Modification of Adiponectin Variants. Patent Application US 20070054359 A1.